Lapatinib, a Dual Inhibitor of ErbB-1/-2 Receptors, Enhances Effects of Combination Chemotherapy in Bladder Cancer Cells

International Journal of Oncology - Greece
doi 10.3892/ijo_00000244
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Spandidos Publications

Related search

Lapatinib, a TKI Dual Inhibitor of Her1 and Her2 Receptors: Review of the Literature

Journal of Cancer Therapy
2012English

Human Pancreatic Cancer Stem Cells Are Sensitive to Dual Inhibition of IGF-IR and ErbB Receptors

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines

Biomedicines
BiochemistryMedicineGeneticsMolecular Biology
2019English

Stimulatory Effects of the Multi-Kinase Inhibitor Sorafenib on Human Bladder Cancer Cells

British Journal of Pharmacology
Pharmacology
2010English

Hypoxia Enhances the Expression of Plasminogen Activator Inhibitor-1 in Human Lung Cancer Cells, EBC-1.

Tohoku Journal of Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2002English

The Novel mTORC1/2 Dual Inhibitor INK128 Enhances Radiosensitivity of Breast Cancer Cell Line McF-7

International Journal of Oncology
Cancer ResearchOncology
2016English

Genomic Alterations of ERBB Receptors in Cancer: Clinical Implications

Oncotarget
Oncology
2017English

Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and ErbB-2 Receptors

PLoS ONE
Multidisciplinary
2011English

PJ34, an Inhibitor of PARP-1, Suppresses Cell Growth and Enhances the Suppressive Effects of Cisplatin in Liver Cancer Cells

Oncology Reports
MedicineCancer ResearchOncology
1994English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy